IN BRIEF: FDA gives Biogen's BIIB080 Fast Track status for Alzheimer's

2nd April 2025 21:28

Biogen Inc - Cambridge, Massachusetts-based biotechnology company - Announces that the US Food & Drug Administration grants Fast Track designation to BIIB080, an investigational antisense oligonucleotide therapy targeting tau, for the treatment of Alzheimer’s. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.

Priya Singhal, head of development at Biogen says: "We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease." Adds BIIB080 has "promising potential".

Current stock price: USD131.12, down 0.7% in New York on Wednesday

12-month change: down 37%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Get more news and expert articles direct to your inbox